Notice of Intent to Publish a Funding Opportunity Announcement for Translational Neural Devices (R61/R33 - Clinical Trial Optional)

Key Dates

• April 28, 2021 - Translational Neural Devices (UG3/UH3 - Clinical Trials Optional). See Notice RFA-NS-21-021.
• April 28, 2021 - Translational Neural Devices (U44 - Clinical Trials Optional). See Notice RFA-NS-21-022.

National Institute of Neurological Disorders and Stroke (NINDS)

the purpose of this Notice is to announce the intention of National Institutes of Neurological Disorders and Stroke (NINDS) to reissue RFA-NS-21-021 to solicit applications for research pursuing translational activities and small clinical studies to advance the development of low risk therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. 

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. 

The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024.

This NOFO will utilize the R61/R33 activity code. Details of the planned NOFO are provided below.

This NOFO is a renewal of our existing translational devices program RFA-NS-21-021. With this reissue, NINDS will modify the scope such that significant risk technologies are no longer responsive to this program. Activities that would be supported in this reissue include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study (R61 phase), as well as a subsequent small clinical study (R33 phase). This reissue will use a milestone-driven R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature. Support will be provided for up to 5 years, which includes initial support of up to 2 years for the R61 phase, followed by up to 3 years of support for the R33 phase upon successfully meeting R61 milestones.

Funding Information

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time. 

Inquiries

Please direct all inquiries to:

Nick Langhals, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: [email protected]